
Metacrine MTCR
Quarterly report 2022-Q3
added 11-14-2022
Metacrine P/CF Ratio 2011-2026 | MTCR
Annual P/CF Ratio Metacrine
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | -0.337 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.337 | -0.337 | -0.337 |
P/CF Ratio of other stocks in the Biotechnology industry
| Issuer | P/CF Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Scholar Rock Holding Corporation
SRRK
|
-17 | $ 43.62 | -1.33 % | $ 5 B | ||
|
MorphoSys AG
MOR
|
-0.654 | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
-8.36 | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
-4.82 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-0.0018 | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-4.6 | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
-1.3 | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
-2.7 | - | 0.23 % | $ 488 M | ||
|
Akero Therapeutics
AKRO
|
-14.1 | - | - | $ 3.67 B | ||
|
I-Mab
IMAB
|
-0.266 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
11.6 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
1.68 K | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
-5 | - | -0.23 % | $ 916 M | ||
|
Biophytis SA
BPTS
|
-23.1 | - | -13.47 % | $ 169 M | ||
|
Aileron Therapeutics
ALRN
|
-1.71 | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
-0.159 | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
-13.2 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.88 | - | -1.52 % | $ 24.7 M | ||
|
Arena Pharmaceuticals
ARNA
|
-12.5 | - | -6.81 % | $ 3.04 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-0.64 | - | - | $ 26.5 M | ||
|
Avenue Therapeutics
ATXI
|
-0.0603 | - | -52.27 % | $ 4.45 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-0.224 | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
-0.607 | - | -11.76 % | $ 5.79 M | ||
|
Acorda Therapeutics
ACOR
|
-1.2 | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
-0.285 | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
-2.73 | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
-89 | - | - | - | ||
|
Avid Bioservices
CDMO
|
38.7 | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
-0.826 | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-0.401 | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-0.0633 | - | -9.65 % | $ 45.9 M | ||
|
Stoke Therapeutics
STOK
|
44.1 | $ 33.98 | 0.83 % | $ 2.01 B | ||
|
Autolus Therapeutics plc
AUTL
|
-2.05 | $ 1.23 | -5.04 % | $ 314 M | ||
|
EyePoint Pharmaceuticals
EYPT
|
-0.0048 | $ 13.09 | 0.23 % | $ 959 K | ||
|
BeiGene, Ltd.
BGNE
|
-1.8 K | - | 0.49 % | $ 251 B | ||
|
China SXT Pharmaceuticals
SXTC
|
-0.965 | $ 1.38 | 4.55 % | $ 1.96 M | ||
|
Takeda Pharmaceutical Company Limited
TAK
|
0.0201 | $ 18.16 | 0.55 % | $ 28.4 B | ||
|
BioDelivery Sciences International
BDSI
|
7.5 | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
-0.588 | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
-0.024 | - | - | $ 3.74 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
-1.4 | $ 1.07 | -2.29 % | $ 21.9 M | ||
|
Enochian Biosciences
ENOB
|
-14.7 | - | - | $ 40.5 M | ||
|
CureVac N.V.
CVAC
|
-4.82 | - | - | $ 867 M | ||
|
Equillium
EQ
|
-5.19 | $ 2.06 | - | $ 118 M | ||
|
Theravance Biopharma
TBPH
|
3.11 | $ 14.97 | -1.45 % | $ 753 M | ||
|
Eton Pharmaceuticals
ETON
|
53.1 | $ 23.43 | -0.09 % | $ 630 M | ||
|
Bellerophon Therapeutics
BLPH
|
-4.42 | - | -74.18 % | $ 955 K | ||
|
CRISPR Therapeutics AG
CRSP
|
-12.7 | $ 47.18 | -0.79 % | $ 4.24 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
-21.4 | $ 4.46 | 0.22 % | $ 855 M | ||
|
Allakos
ALLK
|
-0.976 | - | - | $ 28.6 M |